Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$3.82 -7.3%	$2.91	$1.60 ▼ $15.04	$103.43M	1.84	256,079 shs	82,824 shs
CMPX Compass Therapeutics	$3.49 +6.4%	$2.89	$1.25 ▼ $4.08	$482.60M	1.49	1.41 million shs	1.40 million shs
CRVS Corvus Pharmaceuticals	$5.41 -1.6%	$4.45	$2.54 ▼ $10.00	$403.12M	0.42	795,710 shs	700,210 shs
IMAB I-Mab	$4.25 -5.6%	$2.96	$0.60 ▼ $5.90	$347.06M	1.38	962,682 shs	1.62 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	+0.07%	+20.33%	+33.27%	+53.54%	-64.99%
CMPX Compass Therapeutics	+4.13%	+17.99%	+2.50%	+54.72%	+160.32%
CRVS Corvus Pharmaceuticals	-0.72%	+5.97%	+18.28%	+44.74%	+35.14%
IMAB I-Mab	-13.13%	-0.44%	+140.64%	+257.14%	+257.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANRO Alto Neuroscience	1.6459 of 5 stars	3.3	1.0	1.1	0.8	1.3
CMPX Compass Therapeutics	2.2155 of 5 stars	3.6	1.0	2.2	3.3	0.0
CRVS Corvus Pharmaceuticals	3.2289 of 5 stars	3.5	2.0	3.7	3.3	0.6
IMAB I-Mab	3.1214 of 5 stars	3.7	5.0	2.7	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANRO Alto Neuroscience	2.57	Moderate Buy	$8.50	122.51% Upside
CMPX Compass Therapeutics	3.10	Buy	$12.89	269.31% Upside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	177.26% Upside
IMAB I-Mab	3.00	Buy	$7.00	64.71% Upside

Current Analyst Ratings Breakdown

Latest ANRO, CMPX, IMAB, and CRVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2025	IMAB I-Mab	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$8.00
8/28/2025	IMAB I-Mab	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/21/2025	IMAB I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
8/20/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.00 ➝ $6.00
8/18/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/12/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
8/12/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
7/9/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/9/2025	IMAB I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
7/1/2025	CMPX Compass Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$9.00
6/27/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $5.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$4.56 per share	N/A
CMPX Compass Therapeutics	$850K	567.76	N/A	N/A	$0.67 per share	5.21
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$1.08 per share	N/A
IMAB I-Mab	$3.89M	89.22	N/A	N/A	$2.41 per share	1.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANRO Alto Neuroscience	-$61.43M	-$2.39	N/A	N/A	N/A	N/A	-44.34%	-36.73%	11/11/2025 (Estimated)
CMPX Compass Therapeutics	-$49.38M	-$0.45	N/A	N/A	N/A	N/A	-53.11%	-46.14%	11/11/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$62.29M	-$1.01	N/A	N/A	N/A	N/A	-28.61%	-18.05%	11/11/2025 (Estimated)
IMAB I-Mab	-$22.23M	N/A	0.00	N/A	N/A	N/A	-19.65%	-18.58%	11/13/2025 (Estimated)

Latest ANRO, CMPX, IMAB, and CRVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2025	Q2 2025	IMAB I-Mab	-$0.10	-$0.07	+$0.03	-$0.07	N/A	N/A
8/13/2025	Q2 2025	ANRO Alto Neuroscience	-$0.57	-$0.65	-$0.08	-$0.65	N/A	N/A
8/11/2025	Q2 2025	CMPX Compass Therapeutics	-$0.13	-$0.14	-$0.01	-$0.14	N/A	N/A
8/7/2025	Q2 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.10	+$0.03	-$0.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMAB I-Mab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANRO Alto Neuroscience	0.18	18.43	18.43
CMPX Compass Therapeutics	N/A	7.66	7.66
CRVS Corvus Pharmaceuticals	N/A	8.91	8.91
IMAB I-Mab	N/A	22.82	22.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANRO Alto Neuroscience	N/A
CMPX Compass Therapeutics	68.43%
CRVS Corvus Pharmaceuticals	46.64%
IMAB I-Mab	38.38%

Insider Ownership

Company	Insider Ownership
ANRO Alto Neuroscience	11.13%
CMPX Compass Therapeutics	29.80%
CRVS Corvus Pharmaceuticals	28.50%
IMAB I-Mab	22.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANRO Alto Neuroscience	N/A	27.08 million	24.06 million	N/A
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
CRVS Corvus Pharmaceuticals	30	74.51 million	53.28 million	Optionable
IMAB I-Mab	380	81.66 million	63.61 million	Optionable

ANRO, CMPX, IMAB, and CRVS Headlines

Recent News About These Companies

Are You Looking for a Top Momentum Pick? Why I-Mab Sponsored ADR (IMAB) is a Great Choice

5 hours ago | zacks.com

Stonepine Capital Management LLC Makes New $398,000 Investment in I-Mab Sponsored ADR $IMAB

August 26 at 7:38 AM | marketbeat.com

HC Wainwright Issues Positive Forecast for I-Mab Earnings

August 26 at 2:25 AM | americanbankingnews.com

HC Wainwright Comments on I-Mab's Q3 Earnings (NASDAQ:IMAB)

August 26 at 2:11 AM | marketbeat.com

I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

August 25 at 7:00 AM | globenewswire.com

I-Mab (NASDAQ:IMAB) Upgraded by Wall Street Zen to "Buy" Rating

August 25 at 3:55 AM | marketbeat.com

Needham & Company LLC Forecasts Strong Price Appreciation for I-Mab (NASDAQ:IMAB) Stock

August 23, 2025 | marketbeat.com

I-Mab's (IMAB) Buy Rating Reiterated at HC Wainwright

August 23, 2025 | marketbeat.com

I-Mab (NASDAQ:IMAB) Announces Earnings Results, Beats Estimates By $0.03 EPS

August 22, 2025 | marketbeat.com

I-Mab's (IMAB) "Buy" Rating Reiterated at HC Wainwright

August 22, 2025 | americanbankingnews.com

I-Mab Biopharma: I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update

August 21, 2025 | finanznachrichten.de

I-Mab to Participate in September Investor Conferences

August 21, 2025 | globenewswire.com

I-Mab (IMAB) Expected to Announce Earnings on Wednesday

August 21, 2025 | marketbeat.com

I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update

August 20, 2025 | tmcnet.com

I-Mab price target raised to $6 from $5 at Needham

August 20, 2025 | msn.com

I-Mab Reports Strong Financials and Clinical Progress in August 2025

August 20, 2025 | msn.com

I MAB (ADS) options imply 11.8% move in share price post-earnings

August 19, 2025 | msn.com

Ground Swell Capital LLC Takes Position in I-Mab Sponsored ADR (NASDAQ:IMAB)

August 17, 2025 | marketbeat.com

I-Mab (NASDAQ:IMAB) Trading 14.1% Higher - Here's Why

August 12, 2025 | marketbeat.com

I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers

August 11, 2025 | taiwannews.com.twT

Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies

August 6, 2025 | pharmiweb.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO, CMPX, IMAB, and CRVS Company Descriptions

Alto Neuroscience NYSE:ANRO

$3.82 -0.30 (-7.28%)

Closing price 03:59 PM Eastern

Extended Trading

$3.86 +0.05 (+1.18%)

As of 05:29 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Compass Therapeutics NASDAQ:CMPX

$3.49 +0.21 (+6.40%)

Closing price 04:00 PM Eastern

Extended Trading

$3.43 -0.06 (-1.69%)

As of 05:39 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Corvus Pharmaceuticals NASDAQ:CRVS

$5.41 -0.09 (-1.64%)

Closing price 04:00 PM Eastern

Extended Trading

$5.49 +0.08 (+1.48%)

As of 04:53 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

I-Mab NASDAQ:IMAB

$4.25 -0.25 (-5.56%)

Closing price 04:00 PM Eastern

Extended Trading

$4.42 +0.18 (+4.12%)

As of 05:24 PM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time